section name header

Pronunciation

DA-na-zole

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: androgens

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Absorbed from the GI tract.

Distribution: Unknown.

Metabolism/Excretion: Metabolized by the liver.

Half-life: 4.5 hr.

Time/Action Profile

(disease response)

ROUTEONSETPEAKDURATION
PO (endometriosis)unknown6–8 wk60–90 days
PO (fibrocystic disease)1 mo2–6 mo1 yr
PO (angioedema)unknown1–3 mounknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema.

Derm: acne, hirsutism, oiliness.

EENT: deepening of voice.

Endo: breast size (women), amenorrhea, anovulation, libido.

GI: hepatitis (cholestatic jaundice).

GU: amenorrhea, clitoral enlargement, testicular atrophy.

Metab: weight gain.

Neuro: emotional lability.

Interactions

Drug-Drug:

Route/Dosage

Endometriosis

Fibrocystic Breast Disease

Hereditary Angioedema

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Danocrine

Canadian Brand Names

Cyclomen